Bladder cancer and exeRcise trAining during intraVesical thErapy-the BRAVE trial: a study protocol for a prospective, single-centre, phase II randomised controlled trial

Fernanda Z Arthuso, Adrian S Fairey, Normand G Boulé, Kerry S Courneya, Fernanda Z Arthuso, Adrian S Fairey, Normand G Boulé, Kerry S Courneya

Abstract

Introduction: Non-muscle invasive bladder cancer (NMIBC) accounts for about 75% of newly diagnosed bladder cancers. The treatment for NMIBC involves surgical removal of the tumour followed by 6 weekly instillations of immunotherapy or chemotherapy directly into the bladder (ie, intravesical therapy). NMIBC has a high rate of recurrence (31%-78%) and progression (15%). Moreover, bladder cancer and its treatment may affect patient functioning and quality of life. Exercise is a safe and effective intervention for many patient with cancer groups, however, no studies have examined exercise during intravesical therapy for NMIBC. The primary objective of the Bladder cancer and exeRcise trAining during intraVesical thErapy (BRAVE) trial is to examine the safety and feasibility of an exercise intervention in patients with bladder cancer undergoing intravesical therapy. The secondary objectives are to investigate the preliminary efficacy of exercise on health-related fitness and patient-reported outcomes; examine the social cognitive predictors of exercise adherence; and explore the potential effects of exercise on tumour recurrence and progression.

Methods and analysis: BRAVE is a phase II randomised controlled trial that aims to include 66 patients with NMIBC scheduled to receive intravesical therapy. Participants will be randomly assigned to the exercise intervention or usual care. The intervention consists of three supervised, high-intensity interval training sessions per week for 12 weeks. Feasibility will be evaluated by eligibility, recruitment, adherence and attrition rates. Preliminary efficacy will focus on changes in cardiorespiratory fitness and patient-reported outcomes from baseline (prior to intravesical therapy) to pre-cystoscopy (3 months). Cancer outcomes will be tracked at 3 months, and 1-year follow-up by cystoscopy. Analysis of covariance will compare between-group differences at post-intervention (pre-cystoscopy) for all health-related fitness and patient-reported outcomes.

Ethics and dissemination: The study was approved by the Health Research Ethics Board of Alberta-Cancer Committee (#20-0184). Dissemination will include publication and presentations at scientific conferences and public channels.

Trial registration number: NCT04593862; Pre-results.

Keywords: bladder disorders; clinical trials; oncology.

Conflict of interest statement

Competing interests: None declared.

© Author(s) (or their employer(s)) 2021. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.

Figures

Figure 1
Figure 1
Proposed participant flow diagram for the BRAVE (Bladder cancer and exeRcise trAining during intraVesical thErapy) trial with estimated rates for feasibility.
Figure 2
Figure 2
The BRAVE (Bladder cancer and exeRcise trAining during intraVesical thErapy) trial within non-muscle invasive bladder cancer treatment timeline.
Figure 3
Figure 3
High-intensity interval training protocol in the BRAVE (Bladder cancer and exeRcise trAining during intraVesical thErapy) trial. VO2peak: peak oxygen consumption
Figure 4
Figure 4
The 12-week high-intensity interval training periodisation scheme and the assessment time points in the BRAVE (Bladder cancer and exeRcise trAining during intraVesical thErapy) trial. VO2peak: peak oxygen consumption

References

    1. National Comprehensive Cancer Network [NCCN] . NCCN clinical practice guidelines on oncology: bladder cancer, 2019.
    1. Kassouf W, Traboulsi SL, Kulkarni GS, et al. . CUA guidelines on the management of non-muscle invasive bladder cancer. Can Urol Assoc J 2015;9:E690–704. 10.5489/cuaj.3320
    1. Fujii Y. Prediction models for progression of non-muscle-invasive bladder cancer: a review. Int J Urol 2018;25:212–8. 10.1111/iju.13509
    1. Avritscher EBC, Cooksley CD, Grossman HB, et al. . Clinical model of lifetime cost of treating bladder cancer and associated complications. Urology 2006;68:549–53. 10.1016/j.urology.2006.03.062
    1. Smith AB, Jaeger B, Pinheiro LC, et al. . Impact of bladder cancer on health-related quality of life. BJU Int 2018;121:549–57. 10.1111/bju.14047
    1. Sturgeon KM, Deng L, Bluethmann SM, et al. . A population-based study of cardiovascular disease mortality risk in US cancer patients. Eur Heart J 2019;40:3889–97. 10.1093/eurheartj/ehz766
    1. Schmitz KH, Courneya KS, Matthews C, et al. . American College of sports medicine roundtable on exercise guidelines for cancer survivors. Med Sci Sports Exerc 2010;42:1409–26. 10.1249/MSS.0b013e3181e0c112
    1. Rammant E, Decaestecker K, Bultijnck R, et al. . A systematic review of exercise and psychosocial rehabilitation interventions to improve health-related outcomes in patients with bladder cancer undergoing radical cystectomy. Clin Rehabil 2018;32:594–606. 10.1177/0269215517746472
    1. Banerjee S, Manley K, Thomas L, et al. . O2 preoperative exercise protocol to aid recovery of radical cystectomy: results of a feasibility study. Eur Urol Suppl 2013;12:125. 10.1016/S1569-9056(13)62320-9
    1. Jensen BT, Jensen JB, Laustsen S, et al. . Multidisciplinary rehabilitation can impact on health-related quality of life outcome in radical cystectomy: secondary reported outcome of a randomized controlled trial. J Multidiscip Healthc 2014;7:301–11. 10.2147/JMDH.S62172
    1. Banerjee S, Manley K, Shaw B, et al. . Vigorous intensity aerobic interval exercise in bladder cancer patients prior to radical cystectomy: a feasibility randomised controlled trial. Support Care Cancer 2018;26:1515–23. 10.1007/s00520-017-3991-2
    1. Porserud A, Sherif A, Tollbäck A. The effects of a physical exercise programme after radical cystectomy for urinary bladder cancer. A pilot randomized controlled trial. Clin Rehabil 2014;28:451–9. 10.1177/0269215513506230
    1. Jensen BT, Petersen AK, Jensen JB, et al. . Efficacy of a multiprofessional rehabilitation programme in radical cystectomy pathways: a prospective randomized controlled trial. Scand J Urol 2015;49:133–41. 10.3109/21681805.2014.967810
    1. Jensen BT, Laustsen S, Jensen JB, et al. . Exercise-based pre-habilitation is feasible and effective in radical cystectomy pathways-secondary results from a randomized controlled trial. Support Care Cancer 2016;24:3325–31. 10.1007/s00520-016-3140-3
    1. Minnella EM, Awasthi R, Bousquet-Dion G, et al. . Multimodal prehabilitation to enhance functional capacity following radical cystectomy: a randomized controlled trial. Eur Urol Focus 2021;7:132–8. 10.1016/j.euf.2019.05.016
    1. Chan A-W, Tetzlaff JM, Gøtzsche PC, et al. . Spirit 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ 2013;346:e7586. 10.1136/bmj.e7586
    1. Eldridge SM, Chan CL, Campbell MJ, et al. . Consort 2010 statement: extension to randomised pilot and feasibility trials. BMJ 2016;355:i5239. 10.1136/bmj.i5239
    1. Warburton DE, Jamnik VK, Bredin SS. The 2011 physical activity readiness questionnaire for everyone (PAR-Q+) and the electronic physical activity readiness medical examination (ePARmed-X+). Heal Fit J Canada 2011.
    1. Liguori G, Feito Y, Fountaine C. ACSM’s Guidelines for Exercise Testing and Prescription. Eleventh edition. Philadelphia: Wolters Kluwer, 2021.
    1. Rock CL, Doyle C, Demark-Wahnefried W, et al. . Nutrition and physical activity guidelines for cancer survivors. CA Cancer J Clin 2012;62:243–74. 10.3322/caac.21142
    1. Godin G, Shephard RJ. A simple method to assess exercise behavior in the community. Can J Appl Sport Sci 1985;10:141–6.
    1. Surveillance & Reporting . The 2019 report on cancer statistics in Alberta Edmonton: CancerControl Alberta, Alberta health services, 2019. Available: [Accessed 07 Sep 2020].
    1. Riebe D, Ehrman JK, Liguori G. ACSM’s Guidelines for Exercise Testing and Prescription. Tenth edition. Philadelphia: Wolters Kluwer, 2018.
    1. Garber CE, Blissmer B, Deschenes MR, et al. . American College of sports medicine position stand. quantity and quality of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011;43:1334–59. 10.1249/MSS.0b013e318213fefb
    1. Borg GA. Psychophysical bases of perceived exertion. Med Sci Sports Exerc 1982;14:377–81.
    1. McInnis KJ, Balady GJ. Comparison of submaximal exercise responses using the Bruce vs modified Bruce protocols. Med Sci Sports Exerc 1994;26:103–7.
    1. American Thoracic Society, American College of Chest Physicians . ATS/ACCP statement on cardiopulmonary exercise testing. Am J Respir Crit Care Med 2003;167:211–77. 10.1164/rccm.167.2.211
    1. Beaver WL, Wasserman K, Whipp BJ. A new method for detecting anaerobic threshold by gas exchange. J Appl Physiol 1986;60:2020–7. 10.1152/jappl.1986.60.6.2020
    1. Jones CJ, Rikli RE. Measuring functional: the Journal on active aging, 2002. Available: [Accessed 17 May 2020].
    1. Gonzalez MC, Mehrnezhad A, Razaviarab N, et al. . Calf circumference: cutoff values from the NHANES 1999-2006. Am J Clin Nutr 2021;113:1679–87. 10.1093/ajcn/nqab029
    1. Aaronson NK, Ahmedzai S, Bergman B, et al. . The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993;85:365–76. 10.1093/jnci/85.5.365
    1. Blazeby JM, Hall E, Aaronson NK, et al. . Validation and reliability testing of the EORTC QLQ-NMIBC24 questionnaire module to assess patient-reported outcomes in non-muscle-invasive bladder cancer. Eur Urol 2014;66:1148–56. 10.1016/j.eururo.2014.02.034
    1. Simard S, Savard J. Fear of cancer recurrence inventory: development and initial validation of a multidimensional measure of fear of cancer recurrence. Support Care Cancer 2009;17:241–51. 10.1007/s00520-008-0444-y
    1. Spielberger CD. State‐Trait anxiety inventory. Wiley Online Library, 2010.
    1. Lewinsohn PM, Seeley JR, Roberts RE, et al. . Center for epidemiologic studies depression scale (CES-D) as a screening instrument for depression among community-residing older adults. Psychol Aging 1997;12:277–87. 10.1037//0882-7974.12.2.277
    1. Yellen SB, Cella DF, Webster K, et al. . Measuring fatigue and other anemia-related symptoms with the functional assessment of cancer therapy (fact) measurement system. J Pain Symptom Manage 1997;13:63–74. 10.1016/s0885-3924(96)00274-6
    1. Cohen S, Kamarck T, Mermelstein R. Perceived stress scale. Measuring stress: a guide for health and social scientists, 1994.
    1. Rosenberg M. Rosenberg self-esteem scale (Rse). Acceptance and commitment therapy measures package, 1965.
    1. Bastien CH, Vallières A, Morin CM. Validation of the insomnia severity index as an outcome measure for insomnia research. Sleep Med 2001;2:297–307. 10.1016/s1389-9457(00)00065-4
    1. Ajzen I. The theory of planned behavior. Organ Behav Hum Decis Process 1991:179–211.
    1. Borm GF, Fransen J, Lemmens WAJG. A simple sample size formula for analysis of covariance in randomized clinical trials. J Clin Epidemiol 2007;60:1234–8. 10.1016/j.jclinepi.2007.02.006
    1. Royston P. Multiple imputation of missing values. Stata J 2004;4:227–41. 10.1177/1536867X0400400301
    1. Armijo-Olivo S, Warren S, Magee D. Intention to treat analysis, compliance, Drop-outs and how to deal with missing data in clinical research: a review. Physical Therapy Reviews 2009;14:36–49. 10.1179/174328809X405928
    1. Zuniga KB, Graff RE, Feiger DB, et al. . Lifestyle and non-muscle invasive bladder cancer recurrence, progression, and mortality: available research and future directions. Bladder Cancer 2020;6:9–23. 10.3233/blc-190249
    1. Bowen DJ, Kreuter M, Spring B, et al. . How we design feasibility studies. Am J Prev Med 2009;36:452–7. 10.1016/j.amepre.2009.02.002
    1. Milanović Z, Sporiš G, Weston M. Effectiveness of high-intensity interval training (HIT) and continuous endurance training for VO2max improvements: a systematic review and meta-analysis of controlled trials. Sports Med 2015;45:1469–81. 10.1007/s40279-015-0365-0
    1. Batacan RB, Duncan MJ, Dalbo VJ, et al. . Effects of high-intensity interval training on cardiometabolic health: a systematic review and meta-analysis of intervention studies. Br J Sports Med 2017;51:494–503. 10.1136/bjsports-2015-095841
    1. Wewege MA, Ahn D, Yu J, et al. . High-Intensity interval training for patients with cardiovascular Disease-Is it safe? A systematic review. J Am Heart Assoc 2018;7:e009305. 10.1161/JAHA.118.009305
    1. Blackwell JEM, Doleman B, Herrod PJJ, et al. . Short-Term (<8 wk) High-Intensity Interval Training in Diseased Cohorts. Med Sci Sports Exerc 2018;50:1740–9. 10.1249/MSS.0000000000001634
    1. Wallen MP, Hennessy D, Brown S, et al. . High-Intensity interval training improves cardiorespiratory fitness in cancer patients and survivors: a meta-analysis. Eur J Cancer Care 2020;29:e13267. 10.1111/ecc.13267
    1. Licker M, Karenovics W, Diaper J, et al. . Short-Term Preoperative High-Intensity Interval Training in Patients Awaiting Lung Cancer Surgery: A Randomized Controlled Trial. J Thorac Oncol 2017;12:323–33. 10.1016/j.jtho.2016.09.125
    1. Dunne DFJ, Jack S, Jones RP, et al. . Randomized clinical trial of prehabilitation before planned liver resection. Br J Surg 2016;103:504–12. 10.1002/bjs.10096
    1. Adams SC, DeLorey DS, Davenport MH, et al. . Effects of high-intensity aerobic interval training on cardiovascular disease risk in testicular cancer survivors: a phase 2 randomized controlled trial. Cancer 2017;123:4057–65. 10.1002/cncr.30859
    1. Kang D-W, Fairey AS, Boulé NG, et al. . Exercise duRing active surveillance for prostatE cancer-the erase trial: a study protocol of a phase II randomised controlled trial. BMJ Open 2019;9:e026438. 10.1136/bmjopen-2018-026438
    1. Kang D-W, Fairey AS, Boulé NG, et al. . Effects of exercise on cardiorespiratory fitness and biochemical progression in men with localized prostate cancer under active surveillance: the erase randomized clinical trial. JAMA Oncol 2021. 10.1001/jamaoncol.2021.3067. [Epub ahead of print: 19 Aug 2021].
    1. Devin JL, Sax AT, Hughes GI, et al. . The influence of high-intensity compared with moderate-intensity exercise training on cardiorespiratory fitness and body composition in colorectal cancer survivors: a randomised controlled trial. J Cancer Surviv 2016;10:467–79. 10.1007/s11764-015-0490-7
    1. Morielli AR, Usmani N, Boulé NG, et al. . Exercise during and after neoadjuvant rectal cancer treatment (the exert trial): study protocol for a randomized controlled trial. Trials 2018;19:35. 10.1186/s13063-017-2398-1
    1. Schulz SVW, Laszlo R, Otto S, et al. . Feasibility and effects of a combined adjuvant high-intensity interval/strength training in breast cancer patients: a single-center pilot study. Disabil Rehabil 2018;40:1501–8. 10.1080/09638288.2017.1300688
    1. Schmitt J, Lindner N, Reuss-Borst M, et al. . A 3-week multimodal intervention involving high-intensity interval training in female cancer survivors: a randomized controlled trial. Physiol Rep 2016;4:e12693. 10.14814/phy2.12693
    1. Blackwell JEM, Doleman B, Boereboom CL, et al. . High-Intensity interval training produces a significant improvement in fitness in less than 31 days before surgery for urological cancer: a randomised control trial. Prostate Cancer Prostatic Dis 2020;23:696–704. 10.1038/s41391-020-0219-1
    1. Ramos JS, Dalleck LC, Tjonna AE, et al. . The impact of high-intensity interval training versus moderate-intensity continuous training on vascular function: a systematic review and meta-analysis. Sports Med 2015;45:679–92. 10.1007/s40279-015-0321-z
    1. Williams CJ, Gurd BJ, Bonafiglia JT, et al. . A Multi-Center Comparison of O2peak Trainability Between Interval Training and Moderate Intensity Continuous Training. Front Physiol 2019;10:19. 10.3389/fphys.2019.00019
    1. Wen D, Utesch T, Wu J, et al. . Effects of different protocols of high intensity interval training for VO2max improvements in adults: A meta-analysis of randomised controlled trials. J Sci Med Sport 2019;22:941–7. 10.1016/j.jsams.2019.01.013
    1. Taylor JL, Holland DJ, Keating SE, et al. . Short-Term and long-term feasibility, safety, and efficacy of high-intensity interval training in cardiac rehabilitation: the FITR heart study randomized clinical trial. JAMA Cardiol 2020;5:1382–9. 10.1001/jamacardio.2020.3511
    1. Brown JC, Winters-Stone K, Lee A, et al. . Cancer, physical activity, and exercise. Compr Physiol 2012;2:2775–809. 10.1002/cphy.c120005
    1. Matthews CE, Moore SC, Arem H, et al. . Amount and intensity of leisure-time physical activity and lower cancer risk. J Clin Oncol 2020;38:686–97. 10.1200/JCO.19.02407
    1. Davey Smith G, Shipley MJ, Batty GD, et al. . Physical activity and cause-specific mortality in the Whitehall study. Public Health 2000;114:308–15. 10.1016/S0033-3506(00)00353-X
    1. MacInnis MJ, Gibala MJ. Physiological adaptations to interval training and the role of exercise intensity. J Physiol 2017;595:2915–30. 10.1113/JP273196
    1. Helgerud J, Høydal K, Wang E, et al. . Aerobic high-intensity intervals improve VO2max more than moderate training. Med Sci Sports Exerc 2007;39:665–71. 10.1249/mss.0b013e3180304570
    1. Schmid D, Leitzmann MF. Cardiorespiratory fitness as predictor of cancer mortality: a systematic review and meta-analysis. Ann Oncol 2015;26:272–8. 10.1093/annonc/mdu250
    1. Olney N, Wertz T, LaPorta Z, et al. . Comparison of acute physiological and psychological responses between moderate-intensity continuous exercise and three regimes of high-intensity interval training. J Strength Cond Res 2018;32:2130–8. 10.1519/JSC.0000000000002154
    1. Thum JS, Parsons G, Whittle T, et al. . High-Intensity interval training elicits higher enjoyment than moderate intensity continuous exercise. PLoS One 2017;12:e0166299. 10.1371/journal.pone.0166299
    1. Papadopoulos E, Santa Mina D. Can we HIIT cancer if we attack inflammation? Cancer Causes Control 2018;29:7–11. 10.1007/s10552-017-0983-y
    1. Annels NE, Simpson GR, Pandha H. Modifying the non-muscle invasive bladder cancer immune microenvironment for optimal therapeutic response. Front Oncol 2020;10:175. 10.3389/fonc.2020.00175
    1. Campbell WW, Kraus WE, Powell KE, et al. . High-Intensity interval training for cardiometabolic disease prevention. Med Sci Sports Exerc 2019;51:1220–6. 10.1249/MSS.0000000000001934
    1. Ferreira R, Neuparth MJ, Nogueira-Ferreira R, et al. . Exercise training impacts cardiac mitochondrial proteome remodeling in murine urothelial carcinoma. Int J Mol Sci 2018;20:127. 10.3390/ijms20010127
    1. Kamat AM, Sylvester RJ, Böhle A, et al. . Definitions, end points, and clinical trial designs for non-muscle-invasive bladder cancer: recommendations from the International bladder cancer group. J Clin Oncol 2016;34:1935–44. 10.1200/JCO.2015.64.4070

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj